Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Crispr Therapeutics

This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.

Barchart

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger

CRISPR Stock Surges in Recent Weeks: What's Going On?

CRISPR Therapeutics AG (NASDAQ:CRSP) is trending Thursday, up more than 45% over the past month. Here’s a look at what’s driving the move.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

MarketBeat

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Benzinga

Markets Today: Stock Index Futures Climb on Dovish PPI Surprise

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.21%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.37%. U.S. stock index futures this morning are moderately higher after U.S. Mar producer prices rose less than expected, easing inflation concerns. Also, weekly jobless claims rose...

Barchart

People

Cathie Wood

624 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals

61 stories

Vertex Pharmaceuticals

56 stories

First Trust

38 stories

Recursion Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.